Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Unveils Five-Year Plan To Raise Drug Supervision Standards

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA aims to raise drug quality and supervision standards over the next five years to reach international levels and to control risks associated with traditional Chinese medicines, according to Wu Zhen, deputy director of SFDA
Advertisement

Related Content

China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
China’s 2009 Regulatory Changes Will Affect Makers of Drugs, APIs and Devices
Advertisement
UsernamePublicRestriction

Register

SC069860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel